Women occupy a crucial position in the agricultural sector because; they participate in different forms, as entrepreneurs, labourers, and marketers among others. Despite the various responsibilities' women are involved in, such as family and child-care among others; they contribute up to 40% of agricultural GDP. Against this background, this study examined how female participation in agriculture contributes to economic development in selected African countries, which is in line with the United Nations (UN) 2030 Sustainable Development Goals (SDGs 5 & 8; to ensure gender equality, decent work and economic growth respectively). The study engaged a panel data of selected 33 African countries sourced from the World Development Indicators (WDI) and the Human Development Index (HDI) for the period of 2000 - 2018. The study applied the Pooled Ordinary Least Squares (POLS) and the fixed effects method based on Hausman specification result. Findings from the POLS and fixed effect were consistent across sub-regions, showing that, female participation in agriculture, though statistically significant, was negatively related to economic development. This means that a 1% increase in female participation in agriculture may reduce economic development by between 0.06% and 2.7%. On the other hand, across model, female education was found to be statistically significant and positively related to economic development. On the average, increased level of female education may increase economic development by 1.71%. The implication of this is that an increase in female participation in agriculture without the required level of education and training and access to agricultural materials may have a negative impact on economic development. Therefore, the study recommended that female education and training are required to improve economic development in Africa.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.29063/ajrh2021/v25i5s.10 | DOI Listing |
Alzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) is the leading form of senile dementia, affecting ∼6 million Americans and having a national economic impact of $321 billion, numbers expected to double by 2050. The major pathological hallmarks of AD include Amyloid Beta (Aβ) plaques and Tau neurofibrillary tangles (NFT). The first goal of this research was to develop novel forms of carbon dots (CD) using various precursors.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.
View Article and Find Full Text PDFBackground: The LatAm-FINGERS trial marks a pioneering initiative as the first non-pharmacological clinical trial encompassing participants from 12 Latin American countries, including Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Dominican Republic, Mexico, Peru, Puerto Rico, and Uruguay. This initiative represents a significant advancement in promoting inclusivity and diversity in clinical trial recruitment, particularly in underserved populations.
Method: The LatAm-FINGERS trial is a multicenter randomized clinical trial evaluating a lifestyle intervention tailored for the Latin American population.
Alzheimers Dement
December 2024
Center for Life Ethics, University of Bonn, Bonn, Germany.
Background: Projected Alzheimer's disease (AD) prevalence is expected to fourfold by 2050. With the escalating numbers of individuals affected by neurodegenerative diseases, including Parkinson's disease (PD) and AD, associated challenges encompass increased burdens on individuals and families, societal and political implications and economic impacts. Integrating patient and caregiver perspectives is essential to creating comprehensive, patient-centered care models that promote well-being and resilience in the face of degenerative neurological diseases such as AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!